Freestone Grove Partners LP Buys New Shares in Qiagen (NYSE:QGEN)

Freestone Grove Partners LP bought a new stake in shares of Qiagen (NYSE:QGEN - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 529,617 shares of the company's stock, valued at approximately $23,584,000. Freestone Grove Partners LP owned about 0.24% of Qiagen at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Brown Brothers Harriman & Co. acquired a new position in shares of Qiagen during the fourth quarter valued at $37,000. Geneos Wealth Management Inc. grew its position in Qiagen by 41.5% in the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company's stock worth $38,000 after buying an additional 251 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Qiagen by 152.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock worth $39,000 after acquiring an additional 526 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Qiagen during the 3rd quarter worth about $53,000. Finally, Smartleaf Asset Management LLC raised its holdings in shares of Qiagen by 148.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock valued at $63,000 after acquiring an additional 835 shares during the period. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on QGEN. Baird R W cut shares of Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. Redburn Atlantic lowered Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Robert W. Baird raised their price objective on shares of Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Finally, UBS Group dropped their price target on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Qiagen presently has an average rating of "Hold" and an average price target of $48.42.

Qiagen Price Performance

Shares of Qiagen stock traded up $0.03 during midday trading on Wednesday, reaching $42.20. The company had a trading volume of 676,006 shares, compared to its average volume of 1,285,243. The company has a market capitalization of $9.38 billion, a price-to-earnings ratio of 117.49, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38. The stock has a fifty day simple moving average of $40.43 and a 200 day simple moving average of $41.73. Qiagen has a 1-year low of $37.63 and a 1-year high of $49.30.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. As a group, equities research analysts forecast that Qiagen will post 2.26 earnings per share for the current year.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.